

# Vita 34 AG

#### **BUY (BUY) | Target EUR 6.30 (EUR 6.30)**

Price (last closing price): EUR 5.10 | Upside: 23.5 %

#### E.st. change 2015e 2016e

## International expansion on track


3m

12m

-26%

ns

#### Tuesday, 13 January 2015



Capital		
V3V GY   V3VGn.f		
Market Cap (EURm)		15.4
Enterprise value (EURm)		12.3
Extrema 12 months	7.8	3.6
Free Float (%)		60.2%

Performance (%)

Absolute	1.0	28.4	22.7
Perf. rel. "sector"	-3.1	19.9	2.0
Perf. rel. CDAX	-1.1	14.8	18.7
P&L	12/14e	12/15e	12/16e
Sales (EURm)	13.6	14.8	15.2
EBITDA (EURm)	2.8	3.1	3.3
EBIT (EURm)	1.6	1.9	2.1
Attr. net profit (EURm)	1.1	1.3	1.4
EPS (EUR)	0.37	0.43	0.46
Dividend (EUR)	0.00	0.00	0.00
P/E (x)	13.6	11.9	11.0
P/B (x)	0.7	0.7	0.6
Dividend yield (%)	0%	0%	0%
FCF yield (%)	6%	8%	11%
EV/Sales (x)	0.9	0.8	8.0
EV/EBITDA (x)	4.4	3.9	3.7
EV/EBIT (x)	7.8	6.5	6.0

N	ext	Ev	ents

Net Debt/EBITDA(x)

Gearing (%)

FY14 results 26 March 2015

### New partner in east Europe

Vita 34 has published the second announcement, shortly after their revealing acquisition plans in Austria, pointing out the further international expansion of their market presence. In early January, Vita 34 finalized a cooperation agreement with the Lithuanian stem cell bank KLB Imunolita (founded in 2006), which is active in the Baltic states of Estonia, Latvia and Lithuania. According to the contract, Imunolita will use the collection package of Vita 34 and will additionally offer umbilical cord blood storage in Germany. Furthermore, a cooperation agreement with another sales partner is planned for Hungary in 1H15. Thus, Vita 34 will operate in more than 20 countries.

#### Complete takeover of Secuvita S.L., Spain

For quite some time now, Vita 34 has planned to acquire the remaining minority interest of 12% in Secuvita S.L.. This should now happen in 1Q 2015. No further details on this deal have been disclosed so far.

#### Key takeaways

- (1) With roughly 6m inhabitants, the revenue potential from the Baltic markets is rather limited, in our view. In addition, sales from Imunolita are not expected to have a full impact before 2H15E.
- (2) Strong criticism still envelopes the Spanish subsidiary and its complete takeover, although Spain, due to the population size and culture, has significant market potential. However, we do not expect an improvement of the current market situation and performance in short term. Since Vita 34 will own 100% of the subsidiary, this will consequently affect the net income after minorities. The total loss of Secuvita will now be fully internalized by Vita 34.

#### Changes in estimates

For the time being, we leave our top-line estimates unchanged until we have further information on the revenue impact from Imunolita. Given the planned full consolidation of Secuvita, we have adjusted the net income and EPS estimates accordingly (EPS -3% in 2015E and 2016E). Nevertheless, the realization of the strategic goal of geographical expansion is encouraging and we reiterate our BUY recommendation with a target price of EUR 6.30.

Brigitte Julie Thomalla (Analyst) +49 (0)69 920 54 824

Igor Kim (Analyst) +49 (0)69 920 54 815 brigitte.thomalla@oddoseydler.com igor.kim@oddoseydler.com



IFRS EUR m	2008	2009	2010	2011	2012	2013	2014E	2015E	2016E	2017E
Revenues	15.0	15.1	17.0	16.0	13.6	13.6	13.6	14.8	15.2	15.5
YoY growth	-3.0%	0.9%	12.4%	-5.7%	-15.0%	-0.4%	0.1%	9.0%	2.6%	2.3%
Cost of sales	-5.1	-5.0	-6.1	-6.5	-5.6	-5.5	-5.5	-5.9	-6.0	-6.2
as % of sales	34.4%	32.8%	36.2%	40.9%	40.9%	40.5%	40.7%	39.6%	39.6%	39.6%
Gross profit	9.8	10.1	10.8	9.5	8.0	8.1	8.0	8.9	9.2	9.4
as % of sales	65.6%	67.2%	63.8%	59.1%	59.1%	59.5%	59.3%	60.4%	60.4%	60.4%
Other operating income	0.7	0.6	1.1	0.6	0.7	1.4	1.4	1.4	1.5	1.5
as % of sales	4.9%	3.7%	6.6%	3.8%	5.5%	10.2%	10.4%	9.7%	9.8%	9.8%
Selling expenses	-9.6	-7.6	-7.2	-7.0	-5.8	-4.7	-4.8	-5.1	-5.2	-5.3
as % of sales	64.4%	50.5%	42.7%	43.6%	42.4%	34.7%	35.4%	34.3%	34.3%	34.3%
Administrative expenses	-2.9	-2.8	-3.0	-2.9	-3.1	-2.9	-3.0	-3.2	-3.3	-3.3
as % of sales	19.6%	18.3%	18.0%	18.3%	22.7%	21.4%	22.0%	21.5%	21.5%	21.5%
Other operating expenses	-0.2	-0.1	-0.9	-0.5	-0.7	-0.4	-0.1	-0.2	-0.1	-0.1
as % of sales	1.6%	0.9%	5.4%	3.1%	5.0%	2.9%	0.7%	1.3%	0.7%	0.7%
EBITDA	-1.8	0.7	1.7	0.6	0.4	2.7	2.8	3.1	3.3	3.4
as % of sales	-12.2%	4.9%	9.9%	4.0%	3.0%	19.6%	20.5%	21.1%	21.8%	21.9%
Depreciation and amortisation	-0.4	-0.6	-0.9	-1.0	-1.2	-1.2	-1.2	-1.2	-1.3	-1.3
as % of sales	3.0%	3.8%	5.6%	6.1%	8.5%	8.8%	8.9%	8.2%	8.3%	8.3%
EBIT	-2.3	0.2	0.7	-0.3	-0.7	1.5	1.6	1.9	2.1	2.1
as % of sales	-15.2%	1.1%	4.4%	-2.1%	-5.5%	10.8%	11.6%	12.9%	13.6%	13.6%
EBT (Earnings before income taxes)	-2.4	0.7	0.7	-0.5	-0.9	1.3	1.6	1.9	2.1	2.1
as % of sales	-15.9%	4.4%	3.9%	-3.1%	-6.3%	9.9%	11.8%	12.9%	13.6%	13.6%
Income taxes	0.4	-0.1	-0.3	1.7	0.2	-0.6	-0.5	-0.6	-0.7	-0.7
as % of EBT	17.5%	9.4%	47.6%	340.1%	-28.8%	-41.3%	-32.0%	-32.0%	-32.0%	-32.0%
Net income	-2.0	0.6	0.3	1.2	-0.6	0.8	1.1	1.3	1.4	1.4
as % of sales Thereof:	-13.1%	3.9%	2.1%	7.4%	-4.5%	5.8%	8.0%	8.8%	9.3%	9.2%
Non controlling interests	0.0	0.0	-0.1	-0.1	0.0	-0.1	0.0	0.0	0.0	0.0
Earnings attributable to shareholders	-2.0	0.6	0.5	1.3	-0.6	0.8	1.1	1.3	1.4	1.4
as % of sales	-13.1%	3.9%	2.8%	7.9%	-4.3%	6.2%	8.4%	8.8%	9.3%	9.2%
EPS										
Basic EPS in EUR	-0.64	0.23	0.18	0.48	-0.20	0.28	0.37	0.43	0.46	0.47
Diluted EPS in EUR	-0.74	0.23	0.18	0.48	-0.20	0.28	0.37	0.43	0.46	0.47

Source: Company Data, Oddo Seydler Bank AG



IFRS EUR m	2008	2009	2010	2011	2012	2013	2014E	2015E	2016E
Assets									
Non-current assets	19.8	19.4	26.5	27.1	28.4	27.3	27.2	27.2	27.2
% of total assets	65.2%	62.2%	72.4%	77.9%	77.7%	76.6%	74.6%	71.5%	68.5%
Intangible assets	12.8	12.7	20.4	20.1	21.4	21.1	20.8	20.7	20.5
PPE	3.1	3.3	3.8	4.2	4.5	4.8	4.9	5.1	5.2
Investments	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other financial assets	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Deferred tax assets	0.7	0.7	0.0	0.7	0.7	0.0	0.0	0.0	0.0
Non-current trade receivables	2.0	1.8	1.7	1.7	1.4	1.2	1.2	1.2	1.2
Restricted cash	1.1	0.7	0.5	0.4	0.3	0.2	0.2	0.2	0.2
Other long term assets	3.9	3.4	2.3	2.8	2.5	1.4	1.4	1.4	1.4
Current asstes	10.6	11.8	10.1	7.7	8.2	8.3	9.3	10.8	12.5
% of total assets	0.3	37.8%	27.6%	22.1%	22.3%	23.4%	25.4%	28.5%	31.5%
Inventories	0.6	0.6	0.6	0.5	0.6	0.6	0.6	0.6	0.6
Trade receivables	1.6	2.3	2.9	2.7	2.7	2.8	2.7	3.0	3.0
Other receivables and assets	1.1	0.8	1.4	1.4	1.4	2.1	2.1	2.1	2.1
Short-term investments	0.9	2.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0
Cash and cash equivalents	6.4	6.1	3.7	3.0	3.5	2.9	3.8	5.1	6.8
Total assets	30.3	31.2	36.7	34.7	36.6	35.6	36.5	38.0	39.6
Shareholders´equity and liabilities	5								
Shareholders' equity	18.1	18.9	18.8	20.0	20.5	21.3	22.4	23.7	25.1
as % of total equity and liabilities	59.7%	60.6%	51.3%	57.6%	56.0%	59.8%	61.4%	62.3%	63.3%
Equity of shareholder's of Vita 34	18.1	18.9	18.5	19.7	20.3	21.1	22.2	23.5	24.9
Non-controlling interest	0.0	0.0	0.3	0.3	0.2	0.2	0.1	0.1	0.1
Non-current liabilities and provisions	8.6	8.8	10.4	10.5	10.5	10.4	10.4	10.5	10.6
as % of total equity and liabilities	28.3%	28.2%	28.4%	30.4%	28.7%	29.1%	28.6%	27.7%	26.8%
Interest bearing loans	1.5	1.4	1.8	1.8	0.3	0.2	0.2	0.2	0.2
Deferred income	5.4	5.6	5.8	6.8	8.0	8.2	8.2	8.4	8.5
Other non-current liabilities	1.7	1.8	2.8	1.9	2.2	2.0	2.0	2.0	2.0
Current liabilities and provisions	3.6	3.5	7.5	4.2	5.6	4.0	3.7	3.8	3.9
as % of total equity and liabilities	11.9%	11.2%	20.3%	12.1%	15.3%	11.1%	10.0%	10.0%	9.9%
					4.4	1.4	1.6	4 7	1.8
Deferred income	0.5	0.6	1.1	1.2	1.4	1.4	1.0	1.7	1.0
Deferred income Trade payables	0.5 1.1	0.6 0.8	1.1 0.9	1.2 0.6	1.4	1.4	0.8	0.8	0.8
							_		_
Trade payables	1.1	0.8	0.9	0.6	1.2	1.1	0.8	0.8	0.8

Source: Company Data, Oddo Seydler Bank AG

Vita 34 AG Tuesday, 13 January 2015



IFRS EUR m	2008	2009	2010	2011	2012	2013	2014E	2015E	2016E
EBT	-2.4	0.7	0.7	-0.5	-0.9	1.3	1.6	1.9	2.1
Depreciation and amortization	0.4	0.6	0.9	1.0	1.2	1.2	1.2	1.2	1.3
Gains/losses on the disposal of non-current assets	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Other non-chash expenses /income	-0.1	-0.1	-0.1	0.1	0.0	-0.1	0.0	0.0	0.0
Share-based payments expense	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Finance revenue	-0.5	-0.7	-0.2	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1
Finance costs	0.6	0.2	0.3	0.3	0.2	0.2	0.1	0.1	0.1
Increase/decrease in receivables and other assets	-0.8	-0.2	-0.2	0.3	0.5	-0.5	0.1	-0.3	0.0
Increase/ decrease in inventories	0.0	0.0	-0.1	0.1	0.0	0.1	-0.1	0.0	0.0
Increase/decrease in liabilities	-0.2	0.1	-0.2	-2.7	0.1	-0.1	-0.3	0.0	0.0
Increase/decrease in provisions	-0.2	0.3	-0.3	0.0	0.2	-0.4	-0.1	0.0	0.0
Increase/decrease in deferred income	0.3	0.3	0.3	1.1	1.3	0.2	0.2	0.2	0.2
Interest paid	-0.2	-0.2	-0.3	-0.2	-0.2	-0.1	-0.1	-0.1	-0.1
Income taxes paid	0.0	0.0	0.0	0.0	-0.2	0.0	-0.5	-0.6	-0.7
Cash flow from/ used in operating activities	-2.9	1.1	1.0	-0.7	2.0	1.8	2.0	2.4	2.8
Cash flow from investing activities	0.3	-1.4	-4.5	0.5	-0.9	-0.8	-1.0	-1.1	-1.2
Cash flow from financing activities	0.0	-0.1	1.0	-0.3	-0.8	-1.6	0.0	0.0	0.0
Changes in consolidation scope	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0
Net cash for the period	-2.6	-0.3	-2.6	-0.5	0.5	-0.6	0.9	1.3	1.6
Cash and cash equivalents, beginning of year	9.0	6.4	6.0	3.5	3.0	3.5	2.9	3.8	5.1
Cash and cash equivalents at year's end	6.4	6.0	3.5	3.0	3.5	2.9	3.8	5.1	6.8

Source: Company Data, Oddo Seydler Bank AG



#### **Trading Disclaimer** and statement 34b according German **Securities** Act ("Wertpapierhandelsgesetz") combination with the provisions on financial analysis ("Finanzanalyseverordnung" FinAnV)

This report has been prepared independently of the company analysed by Oddo Seydler Bank AG and/ or its cooperation partners and the analyst(s) mentioned on the front page (hereafter all are jointly and/or individually called the 'author'). None of Oddo Seydler Bank AG or its cooperation partners, the Company or its shareholders has independently verified any of the information given in this document.

Section 34b of the German Securities Trading Act in combination with the FinAnV requires an enterprise preparing a security analysis to point out possible conflicts of interest with respect to the company that is the subject of the analysis.

Oddo Seydler Bank AG is a subsidiary of Oddo & Cie, Paris (hereafter 'Oddo', together 'Oddo Group'). However, Oddo Seydler Bank AG (hereafter 'Oddo Seydler') provides its research work independent from Oddo. Oddo Group is offering a wide range of Services not only including investment banking services and liquidity providing services (designated sponsoring). Oddo Group may possess relations to the covered companies as follows (additional information and disclosures will be made available upon request):

- a. Oddo Group holds more than 5% interest in the capital stock of the company that is subject of the analysis.
- b. Oddo Group was a participant in the management of a (co)consortium in a selling agent function for the issuance of financial instruments, which themselves or their issuer is the subject of this financial analysis within the last twelve months.
- c. Oddo Group has provided investment banking and/or consulting services during the last 12 months for the company analysed for which compensation has been or will be paid for.
- d. Oddo Group acts as designated sponsor for the company's securities on the basis of an existing designated sponsorship contract. The services include the provision of bid and ask offers. Due to the designated sponsoring service agreement Oddo Group may regularly possess shares of the company and receives a compensation and/ or provision for its services.
- e. The designated sponsor service agreement includes a contractually agreed provision for research services.
- f. Oddo Seydler and the analysed company have a contractual agreement about the preparation of research reports. Oddo Seydler receives a compensation in return.
- g. Oddo Group has a significant financial interest in relation to the company that is subject of this analysis.

In this report, the following conflicts of interests are given at the time, when the report has been published: d,f

Oddo Group and/or its employees or clients may take positions in, and may make purchases and/ or sales as principal or agent in the securities or related financial instruments discussed in this analysis. Oddo Group may provide investment banking, consulting, and/ or other services to and/ or serve as directors of the companies referred to in this analysis. No part of the authors compensation was, is or will be directly or indirectly related to the recommendations or views expressed.

#### **Recommendation System:**

Oddo Seydler uses a 3-level absolute share rating system. The ratings pertain to a time horizon of up to 12 months:

BUY: The expected performance of the share price is above +10%.

HOLD: The expected performance of the share price is between 0% and +10%.

SELL: The expected performance of the share price is below 0%.

This rating system is only a guideline. Therefore, deviations from this system may apply.

Recommendation history over the last 12 months for the company analysed in this report:

Date	Recommendation	Price at change date	Price target
13 January 2015	BUY (Update)	EUR 5.10	EUR 6.30
03 December 2014	BUY (Update)	EUR 4.50	EUR 6.30
24 October 2014	BUY (Update)	EUR 4.32	EUR 6.00
25 July 2014	BUY (Update)	EUR 4.55	EUR 6.00
13 May 2014	BUY (Initial Coverage)	EUR 5.16	EUR 7.10

The following valuation methods are used when valuing companies: Multiplier models (price/earnings, price/cash flow, price/book value, EV/Sales, EV/EBIT, EV/EBITA, EV/EBITDA), peer group comparisons, historical valuation approaches, discounting models (DCF, DDM), break-up value approaches or asset valuation approaches. The valuation models are dependent upon macroeconomic measures such as interest, currencies, raw materials and assumptions concerning the economy. In addition, market moods influence the valuation of companies.



The figures taken from the income statement, the cash flow statement and the balance sheet upon which the evaluation of companies is based are estimates referring to given dates and therefore subject to risks. These may change at any time without prior notice.

The opinions and forecasts contained in this report are those of the author alone. Material sources of information for preparing this report are publications in domestic and foreign media such as information services (including but not limited to Reuters, VWD, Bloomberg, DPA-AFX), business press (including but not limited to Börsenzeitung, Handelsblatt, Frankfurter Allgemeine Zeitung, Financial Times), professional publications, published statistics, rating agencies as well as publications of the analysed issuers. Furthermore, discussions were held with the management for the purpose of preparing the analysis. Potentially parts of the analysis have been provided to the issuer prior to going to press; no significant changes were made afterwards, however. Any information in this report is based on data considered to be reliable, but no representations or guarantees are made by the author with regard to the accuracy or completeness of the data. The opinions and estimates contained herein constitute our best judgment at this date and time, and are subject to change without notice. Possible errors or incompleteness of the information do not constitute grounds for liability, neither with regard to indirect nor to direct or consequential damages. The views presented on the covered company accurately reflect the personal views of the author. All employees of the author's company who are involved with the preparation and/or the offering of financial analyzes are subject to internal compliance regulations.

The report is for information purposes, it is not intended to be and should not be construed as a recommendation, offer or solicitation to acquire, or dispose of, any of the securities mentioned in this report. Any reference to past performance should not be taken as indication of future performance. The author does not accept any liability whatsoever for any direct or consequential loss arising from any use of material contained in this report. The report is confidential and it is submitted to selected recipients only. The report is prepared for professional investors only and it is not intended for private investors. Consequently, it should not be distributed to any such persons. Also, the report may be communicated electronically before physical copies are available. It may not be reproduced (in whole or in part) to any other investment firm or any other individual person without the prior written approval from the author. The author is not registered in the United Kingdom nor with any U.S. regulatory body.

It has not been determined in advance whether and in what intervals this report will be updated. Unless otherwise stated current prices refer to the closing price of the previous trading day. Any reference to past performance should not be taken as indication of future performance. The author maintains the right to change his opinions without notice, i.e. the opinions given reflect the author's judgment on the date of this report.

This analysis is intended to provide information to assist institutional investors in making their own investment decisions, not to provide investment advice to any specific investor.

By accepting this report the recipient accepts that the above restrictions are binding. German law shall be applicable and court of jurisdiction for all disputes shall be Frankfurt am Main (Germany).

This report should be made available in the United States solely to investors that are (i) "major US institutional investors" (within the meaning of SEC Rule 15a-6 and applicable interpretations relating thereto) that are also "qualified institutional buyers" (QIBs) within the meaning of SEC Rule 144A promulgated by the United States Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended (the "Securities Act") or (ii) investors that are not "US Persons" within the meaning of Regulation S under the Securities Act and applicable interpretations relating thereto. The offer or sale of certain securities in the United States may be made to QIBs in reliance on Rule 144A. Such securities may include those offered and sold outside the United States in transactions intended to be exempt from registration pursuant to Regulation S. This report does not constitute in any way an offer or a solicitation of interest in any securities to be offered or sold pursuant to Regulation S. Any such securities may not be offered or sold to US Persons at this time and may be resold to US Persons only if such securities are registered under the Securities Act of 1933, as amended, and applicable state securities laws, or pursuant to an exemption from registration.

This publication is for distribution in or from the United Kingdom only to persons who are authorised persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 of the United Kingdom or any order made there under or to investment professionals as defined in Section 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and is not intended to be distributed or passed on, directly or indirectly, to any other class of persons.

This publication is for distribution in Canada only to pension funds, mutual funds, banks, asset managers and insurance companies.

The distribution of this publication in other jurisdictions may be restricted by law, and persons into whose possession this publication comes should inform themselves about, and observe, any such restrictions. In particular this publication may not be sent into or distributed, directly or indirectly, in Japan or to any resident thereof.

### Vita 34 AG Tuesday, 13 January 2015



Graurheindorferstraße 108 53117 Bonn

and

Marie-Curie-Str. 24-28 60439 Frankfurt

Oddo Seydler Bank AG Schillerstrasse 27 - 29 60313 Frankfurt am Main www.oddoseydler.com Tel.: 0049 - (0)69 - 920 54 800